340 related articles for article (PubMed ID: 16442889)
1. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials.
B-Vitamin Treatment Trialists' Collaboration
Am Heart J; 2006 Feb; 151(2):282-7. PubMed ID: 16442889
[TBL] [Abstract][Full Text] [Related]
2. Homocysteine-lowering trials for prevention of heart disease and stroke.
Clarke R
Semin Vasc Med; 2005 May; 5(2):215-22. PubMed ID: 16047274
[TBL] [Abstract][Full Text] [Related]
3. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
Clarke R; Armitage J
Semin Thromb Hemost; 2000; 26(3):341-8. PubMed ID: 11011852
[TBL] [Abstract][Full Text] [Related]
4. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
5. Homocysteine and coronary heart disease.
Clarke R; Lewington S
Semin Vasc Med; 2002 Nov; 2(4):391-9. PubMed ID: 16222629
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of folic acid supplementation in cardiovascular disease prevention: an updated meta-analysis of randomized controlled trials.
Yang HT; Lee M; Hong KS; Ovbiagele B; Saver JL
Eur J Intern Med; 2012 Dec; 23(8):745-54. PubMed ID: 22884409
[TBL] [Abstract][Full Text] [Related]
7. Homocysteine, folic acid, B vitamins and cardiovascular risk.
Blacher J; Safar ME
J Nutr Health Aging; 2001; 5(3):196-9. PubMed ID: 11458292
[TBL] [Abstract][Full Text] [Related]
8. [Vitamin treatments that lower homocysteine concentration: can they decrease cerebrovascular disease in primary prevention?].
Méndez-González J; Rodríguez-Millán E; Julve J; Blanco-Vaca F
Rev Neurol; 2010 Feb 16-28; 50(4):235-44. PubMed ID: 20198596
[TBL] [Abstract][Full Text] [Related]
9. Homocysteine, B-vitamins and CVD.
McNulty H; Pentieva K; Hoey L; Ward M
Proc Nutr Soc; 2008 May; 67(2):232-7. PubMed ID: 18412997
[TBL] [Abstract][Full Text] [Related]
10. [Homocysteine--risk factor or risk indicator?].
Rafflenbeul W
MMW Fortschr Med; 2005 Nov; 147(44):28-30. PubMed ID: 16302487
[TBL] [Abstract][Full Text] [Related]
11. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials.
Antoniades C; Antonopoulos AS; Tousoulis D; Marinou K; Stefanadis C
Eur Heart J; 2009 Jan; 30(1):6-15. PubMed ID: 19029125
[TBL] [Abstract][Full Text] [Related]
12. Effect of homocysteine interventions on the risk of cardiocerebrovascular events: a meta-analysis of randomised controlled trials.
Mei W; Rong Y; Jinming L; Yongjun L; Hui Z
Int J Clin Pract; 2010 Jan; 64(2):208-15. PubMed ID: 19912385
[TBL] [Abstract][Full Text] [Related]
13. Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia.
Clarke R; Lewington S; Sherliker P; Armitage J
Curr Opin Clin Nutr Metab Care; 2007 Jan; 10(1):32-9. PubMed ID: 17143052
[TBL] [Abstract][Full Text] [Related]
14. Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries.
Galan P; de Bree A; Mennen L; Potier de Courcy G; Preziozi P; Bertrais S; Castetbon K; Hercberg S
J Nutr Health Aging; 2003; 7(6):428-35. PubMed ID: 14625623
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels.
Miller ER; Juraschek S; Pastor-Barriuso R; Bazzano LA; Appel LJ; Guallar E
Am J Cardiol; 2010 Aug; 106(4):517-27. PubMed ID: 20691310
[TBL] [Abstract][Full Text] [Related]
16. Vitamins and stroke: the homocysteine hypothesis still in doubt.
Ntaios GC; Savopoulos CG; Chatzinikolaou AC; Kaiafa GD; Hatzitolios A
Neurologist; 2008 Jan; 14(1):2-4. PubMed ID: 18195649
[TBL] [Abstract][Full Text] [Related]
17. Plasma folate and total homocysteine levels are associated with the risk of myocardial infarction, independently of each other and of renal function.
Van Guelpen B; Hultdin J; Johansson I; Witthöft C; Weinehall L; Eliasson M; Hallmans G; Palmqvist R; Jansson JH; Winkvist A
J Intern Med; 2009 Aug; 266(2):182-95. PubMed ID: 19298497
[TBL] [Abstract][Full Text] [Related]
18. Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?
Lonn E
Curr Opin Hematol; 2007 Sep; 14(5):481-7. PubMed ID: 17934354
[TBL] [Abstract][Full Text] [Related]
19. Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials.
Qin X; Huo Y; Xie D; Hou F; Xu X; Wang X
Clin Nutr; 2013 Oct; 32(5):722-7. PubMed ID: 23313356
[TBL] [Abstract][Full Text] [Related]
20. Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases?
Debreceni B; Debreceni L
Cardiovasc Ther; 2012 Aug; 30(4):227-33. PubMed ID: 21884001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
